The World Health Organization has released its first guidelines on GLP-1 therapies for obesity in adults, recognizing obesity as a chronic disease requiring lifelong care including pharmacotherapy.
1 billion+ affectedGlobal obesity burden driving WHO to issue first-ever GLP-1 therapy guidelines
What the researchers found
WHO now formally recommends GLP-1 therapies as part of integrated, person-centered obesity treatment, recognizing obesity as a chronic disease requiring lifelong management beyond behavioral interventions alone.
Why it matters
WHO guidelines shape healthcare policy worldwide. Their endorsement of GLP-1 drugs for obesity legitimizes pharmacotherapy as a standard treatment approach and could improve access globally, especially in countries that have been slow to adopt these treatments.
How the study worked
WHO clinical practice guideline developed through systematic evidence review and Member State consultation.
What this study cannot tell us
Guidelines may face implementation challenges in low-resource settings where GLP-1 drugs are expensive or unavailable; does not resolve supply shortages or affordability concerns.
How to read the evidence
WHO clinical practice guideline based on comprehensive systematic evidence review — the highest level of institutional endorsement for clinical recommendations.
When this study was published
Published in 2026, representing a landmark moment in global obesity treatment policy.
The bigger picture
This marks a paradigm shift in global obesity management — from viewing it as a lifestyle issue to treating it as a chronic medical condition deserving pharmaceutical intervention, potentially expanding GLP-1 drug access to healthcare systems worldwide.
Questions still open
- Will WHO guidelines accelerate insurance coverage and affordability of GLP-1 drugs in developing countries?
- How will health systems manage the lifelong treatment model when GLP-1 drug supplies are already constrained?
Common questions
What does the WHO guideline mean for people with obesity?
Do the guidelines say everyone with obesity should take GLP-1 drugs?
Read the original research
World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults.
JAMA, 335(5), 434-438
Citation
Celletti, Francesca; Farrar, Jeremy; De Regil, Luz. (2026). World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults.. JAMA, 335(5), 434-438. https://doi.org/10.1001/jama.2025.24288